Georgia's Online Cancer Information Center

Find A Clinical Trial

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Cancer Type
Stomach/ Gastric Cancer
Trial Phase
Phase III
18 - 200 Years, Male and Female
Study Type
Protocol IDs
D910GC00001 (primary)
Study Sponsor
AstraZeneca Pharmaceuticals LP


This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy
Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and
Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).


This study investigates treatment of durvalumab or placebo therapy combined with FLOT
chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) given before surgery
(neoadjuvant) and durvalumab or placebo therapy combined with FLOT chemotherapy after surgery
(adjuvant), will work and be safe for the treatment of resectable (removable by surgery)
gastric or gastroesophageal cancer, and also to better understand the studied disease and
associated health problems.


  1. Patients with histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
  2. Patients must undergo radical surgery.
  3. No prior anti-cancer therapy for the current malignancy.
  4. World Health Organization (WHO)/ECOG performance status of 0 or 1 at enrollment.
  5. Adequate organ and marrow function.
  6. Availability of tumor sample prior to study entry.
  7. Must have a life expectancy of at least 24 weeks.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE


Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.